NIPU Studien:

NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma

https://pubmed.ncbi.nlm.nih.gov/34059094/

Leave a Reply

Your email address will not be published.